Chile - an attractive market after healthcare reforms
This article was originally published in Clinica
Executive Summary
Big market opportunities and fewer import restrictions await companies selling to Latin America, says Silvia Dreyfuss, general manager of the US/Latin America biomedical trading company, LABS. Speaking at the Institute of the Americas' Latin American Health Care Congress, she also listed the disadvantages of dealing with the region, which include slow product introduction and payment delays from customers of between 60 and 120 days.